logo
Plus   Neg
Share
Email

Johnson & Johnson Ordered To Pay $750 Mln In New Jersey Baby Powder Case

A New Jersey jury has ordered Johnson & Johnson (JNJ) to pay $750 million in punitive damages to four cancer victims who charged that the company's Johnson's Baby Powder contained cancer-causing asbestos.

The jury agreed that J&J had acted "maliciously or in wanton disregard" of the safety risks of the four plaintiffs.

"This case is really about the fact that J&J structured their last 50 years of conduct around concealing that there were, and have always been, asbestos fibers in their baby powder," said trial lawyer Chris Panatier of Dallas-based Simon Greenstone Panatier. "They designed test methods that they knew lacked the sensitivity to detect the asbestos that was present and then on the occasions when asbestos was found, took steps to make excuses, blame non-existent contamination, delete and alter test results. The jury saw all of that."

In September, a separate jury found Johnson & Johnson liable in the lawsuit by plaintiffs Douglas Barden, David Etheridge, D'Angela McNeill and Will Ronning and awarded $37.3 million in actual damages.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Hyundai Motor has launched a new IONIQ brand dedicated to battery electric vehicles, as the automaker is accelerating its efforts to gain a share in the fast-growing global EV market. Under the IONIQ brand, Hyundai plans to introduce three new dedicated electric vehicle models over the next four years. Hyundai is South Korea's largest automaker. Amazon.com, Inc. is in talks with mall operator Simon Property Group, Inc. to use the abandoned anchor departmental stores of JC Penny and Sears at their malls as fulfillment centers, reports said. This is expected to help the e-commerce giant in boosting their last mile delivery, which is the last leg of the delivery process. The U.S. Food and Drug Administration announced the approval of Trevena Inc.'s Olinvyk (oliceridine), a new opioid for intravenous use in hospitals or other controlled clinical settings. Olinvyk is an opioid agonist to manage moderate to severe acute pain in adults, where the pain is severe enough to require an intravenous opioid and for whom alternative treatments are inadequate.
Follow RTT